673Wire StoriesBIO-key Expands Product Line and Market Reach with Launch of FIDO2 Compliant Security Keys in a Variety of Form Factors
WALL, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management (IAM)...
- 625Wire Stories
Fabrinet Receives Cisco 2021 EMS Partner of the Year Award
BANGKOK–(BUSINESS WIRE)–#Fabrinet–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services (EMS) to original...
- 640Wire Stories
Fabrinet Receives Cisco 2021 EMS Partner of the Year Award
BANGKOK–(BUSINESS WIRE)–#Fabrinet–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services (EMS) to original...
- 645Wire Stories
Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines
GUANGZHOU, China–(BUSINESS WIRE)–#IBD–Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”) and Intract Pharma (“Intract”) announced a global collaboration and licensing agreement that gives Bio-Thera access...
- 745Wire Stories
Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines
GUANGZHOU, China–(BUSINESS WIRE)–#IBD–Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”) and Intract Pharma (“Intract”) announced a global collaboration and licensing agreement that gives Bio-Thera access...
- 1.4KWire Stories
AnHeart and Innovent Announce Interim Data from Phase ? Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
In the crizotinib treatment-naïve patient group (n=21), the confirmed objective response rate (ORR) was 90.5% (19/21) and the disease control rate (DCR)...
- 1.4KWire Stories
AnHeart and Innovent Announce Interim Data from Phase ? Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
In the crizotinib treatment-naïve patient group (n=21), the confirmed objective response rate (ORR) was 90.5% (19/21) and the disease control rate (DCR)...
- 858Wire Stories
The World Economic Forum Welcomes Western Digital to Prestigious Global Lighthouse Network
Western Digital’s smart facilities in Malaysia and Thailand are the first Lighthouses to be accepted in these countries Award recognizes leadership in...
- 618Wire Stories
D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China
D&D will receive an upfront payment of $4 million and is eligible to receive additional undisclosed milestone payments upon achievement of certain...
- 636Wire Stories
Ingram Micro Commerce & Lifecycle Services Executive Receives Supply Chain Award
AUCKLAND, New Zealand–(BUSINESS WIRE)–#3pl—Ingram Micro Commerce & Lifecycle Services today announced that Lisa Flynn, director, New Zealand, has been recognized in Supply...
